|
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Rapid Initiation for HIV-1 Infection:
Primary Analysis of the DIAMOND Study at ACTHIV
|
|
|
Reported by Jules Levin
13th ANNUAL AMERICAN CONFERENCE FOR
THE TREATMENT OF HIV (ACTHIV); APRIL 11-13,
2019; MIAMI, FLORIDA.
Gregory D. Huhn,1 Gordon Crofoot,2 Moti Ramgopal,3,* Joseph Gathe Jr,4 Robert Bolan,5 Donghan Luo,6 Richard Bruce Simonson,7 Richard E. Nettles,7 Keith Dunn7
1The Ruth M. Rothstein CORE Center, Chicago, IL; 2Crofoot Research Center, Houston, TX; 3Midway Immunology and Research Center, Fort Pierce, FL; 4Therapeutic Concepts, Houston, TX; 5Los Angeles LGBT Center, Los Angeles, CA; 6Janssen Research & Development, LLC, Titusville, NJ; 7Janssen Scientific Affairs, LLC, Titusville, NJ.










REFERENCES
1. Rosen S, et al. PLoS Med. 2016;13(5):e1002015.
2. Koenig SP, et al. PLoS Med. 2017;14(7):e1002357.
3. Labhardt ND, et al. JAMA. 2018;319(11):1103-1112.
4. Coffey S, et al. AIDS. 2018;33(5):825-832.
5. Halperin J, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
6. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. Geneva, Switzerland.
7. Saag MS, et al. JAMA. 2018;320(4):379-396.
8. Lathouwers E, et al. HIV Clin Trials. 2017;18(5-6):196-204.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. US Department of
Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 11, 2019.
10. Woodcock A, Bradley C. Value Health. 2006;9(5):320-333.
11. Andreatta K, et al. Poster presented at: Conference on Retrovirsuses and Opportunistic Infections; March 4-8, 2019; Seattle, WA. Poster 552.
12. Acosta RK, et al. Poster presented at: Conference on Retrovirsuses and Opportunistic Infections; March 4-8, 2019; Seattle, WA. Poster 551.
13. Prevention Access Campaign. Consensus statement. https://www.preventionaccess.org/consensus. Accessed December 19, 2018.
|
|
|
|
|
|
|